Kuros Biosciences ^Company

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the Kingdom of Saudi Arabia, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company has collaborations with Checkmate Pharmaceuticals LLC for the licensing of CYT003 for the treatment of oncology; Pfizer Inc. to develop a novel anti-IgE vaccine; and Singapore’s Agency for Science, Technology and Research, which researches, develops, and commercializes an influenza vaccine. Kuros Biosciences AG was founded in
2000 and is headquartered in Schlieren, Switzerland.